TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of Recovery From Hypoglycemia to Euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incremental Weighted Average Blood Glucose Concentration Over 3 Hours of Hypoglycemic Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CaMKIIγ activation (autophosphorylation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Hamilton Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary Outcome Measure
Endpoint domain: General outcomes
Primary endpoint: Percentage of Participants Fulfilling Protocol-Specified Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Rectal Mucosal CD4+ T Cells Expressing CCR5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of p24 from Rectal Mucosal Explant Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative abundance of Prevotellaceae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of Bacteroidaceae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Informal caregivers with unmet needs
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Positive percentage of total macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 28-day mortality of sepsis patients
Endpoint domain: Mortality/survival
Primary endpoint: Anxiety related to MRI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose of P276-00
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lower limb pronation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of successfully dressed medical stockings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Pain Improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Frequency of adverse events and assessed relationship to study products
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory measures of safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD-4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plagiocephaly severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in wheelchair skills capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in wheelchair skills confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of ventricular beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement of SSADA to conventional angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of GDC-0134
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve Extrapolated to Infinity (AUCinf) of GDC-0134
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net Phosphorous Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Forearm blood flow response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Static and Dynamic Stability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes Self-management Instrument-35 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommended Phase Two Dose (RPTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative attentional bias
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Variation in lean and fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of sargramostim
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication of the Bio-burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Heart Rate Variability-LF Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating Biomarkers--Fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete clinical resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical progression or up-staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Postoperative Healthcare Acquired Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Event Related Potential (ERP) MEG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Visual Analogue Scale (VAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Placebo-corrected change from baseline in QT Interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative return of gastrointestinal (GI) function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of shoulder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of women with no lesions at 12 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of time children's eye gaze is directed toward the target object
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Up to Date Well Child Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Emergency/Urgent Care Utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parent experience of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Isometric Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lesion uptake of 89Zr-Df-IAB22M2C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with malignant ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: No serious device-related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour pharmacokinetics of ellagic acid in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of post-TAVI aortic regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response Rate in Plasma Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GBS disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of endometrial nerve fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Procedure Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dynamometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in functional motor ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of closure of the cystic duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MTCT rates
Endpoint domain: Mortality/survival
Primary endpoint: disappearance of a common palmar or plantar wart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Elasticity of the uterine cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of participants with solicited local Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with solicited systemic Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with unsolicited local and/or systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-Allergic Medication Score (AMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HIV RNA < 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of NIV Support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of NIV Support
Endpoint domain: Adverse events/effects
Primary endpoint: Bilirubin reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Device and Procedure Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Level of altered experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pattern of most occurring altered experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of Executive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients without correct diagnostic and management decisions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Any new stroke event
Endpoint domain: Mortality/survival
Primary endpoint: Severe or moderate bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 24-hour Weighted Mean Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SOT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Times having sex without a condom
Endpoint domain: Adverse events/effects
Primary endpoint: Lung Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in the width of the alveolar bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Rehabilitation Assessment of Movement Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Contribution to Self-Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of Betamimetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of total serum iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of total serum iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Received at Least 5 of the 6 Scheduled Doses of Bevacizumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Joint structure abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in Alzheimer's disease assessment scale-cognitive subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Summary of acute and long term adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioural Measures of Alcohol Intoxication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Any Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: HIV risk behaviors and use of HIV risk prevention strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Doxorubicine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of GI dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of subjects with normal VEMP response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of MBI compared to mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting serum glucose measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin hormone measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Erythropoietin hormone measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thyroxine hormone measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol hormone measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of sagittal abdominal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Accuracy on the EF Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Response Times (RTs) on the EF Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the functional scale assessing the impact of vision loss in everyday life activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Odds ratio of sacroiliac joint dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in fMRI BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in regional cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance scores in cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fugl-Meyer Motor Assessment of the Lower Affected Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Total Percentage of Work Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Work Time Missed
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Impairment while Working
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Total Activity Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: delta PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta BPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Positive and Negative Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HER2-low Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: HER2-low Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Protein uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MRD-Negative Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Omega-3 Fatty Acid Pattern in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parameters of Iron Status in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average of the TSS over the treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average of the VPT measurement over the treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in laboratory parameter values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in vital sign values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine response to SARS-Cov-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Innate immune response to SARS-Cov-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurological damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute level of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in modified Rankin Scale (mRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NIH Stroke Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Montreal Cognitive Assessment test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Enamel thickness reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parent Reported Child Vegetable FFQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum SCUBE 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum SCUBE 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum SCUBE 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bech subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IDS-C scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QIDS-SR16 scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in morning serum levels of pro-inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change From Baseline in Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-10hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained abstinence (from tobacco)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day Point prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Any quit attempt >= 24 hours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in agitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: gene expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methylation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEAEs following IV dosing
Endpoint domain: Adverse events/effects
Primary endpoint: TEAEs following SC dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of responders at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test specificity for colorectal cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of differentially regulated genes on a transcriptomic level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of differentially regulated genes on a lipidome level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of differentially regulated genes on a metabolome level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of differentially regulated genes on a epigenome level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of differentially regulated genes on a proteome level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Success to Prevent Pseudomembranes Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACQ questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: spirometry assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes